Tempus ECG-AF vs syngo MBF
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your primary objective is to proactively identify patients aged 65 or older at an increased risk of developing new-onset atrial fibrillation within the next 12 months, leveraging standard 12-lead ECG recordings. This tool is ideal for integrating into routine geriatric or internal medicine screenings to support earlier detection and follow-up for AF risk.
View Tempus ECG-AF →Choose syngo MBF if…
Choose syngo MBF if you need advanced, quantitative analysis of myocardial blood flow (MBF) and myocardial flow reserve (MFR) using PET imaging for comprehensive cardiac diagnostics. This solution is best suited for detailed assessment of myocardial perfusion, aiding in the diagnosis of coronary artery disease, or evaluating the effectiveness of cardiac therapies through precise imaging data.
View syngo MBF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | syngo MBF |
|---|---|---|
| Pricing | Contact vendor | Contact vendor |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | On-premise (dedicated hardware), Virtualized environments (VMware, Hyper-V) |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Yes AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Tempus ECG-AFTempus ECG-AF integrates directly into existing healthcare facility systems and ECG workflows without requiring a dedicated user interface, minimizing the learning curve and disruption for clinicians. This 'behind-the-scenes' operation makes it highly usable by seamlessly delivering results within familiar clinical environments.
Clinical Value
TieBoth tools are FDA-cleared and offer significant clinical value in distinct areas of cardiology. Tempus ECG-AF provides early risk identification for atrial fibrillation from standard ECGs, enabling proactive patient management. syngo MBF offers advanced quantitative myocardial blood flow analysis using PET imaging, crucial for diagnosing coronary artery disease and assessing therapy response in complex cases.
Pricing & Value
Tempus ECG-AFTempus ECG-AF provides clear transparency regarding its financial value by explicitly stating CMS reimbursement availability with specific CPT codes and a Medicare rate. This information is crucial for healthcare providers to assess the economic viability and facilitates adoption, a level of detail not provided by Tool B.
Enterprise Readiness
syngo MBFBoth tools demonstrate strong regulatory compliance with FDA clearance, HIPAA compliance, and BAA availability. However, Siemens Medical Solutions, as a global leader in medical technology, offers a more established and extensive enterprise infrastructure, including diverse deployment options (on-premise, virtualized) and comprehensive IT care plans for its syngo.via platform.
Innovation
Tempus ECG-AFTempus ECG-AF represents a significant innovation by applying AI to widely available 12-lead ECGs to predict the risk of new-onset atrial fibrillation within 12 months. This predictive capability from a common, inexpensive test has the potential for broad impact on preventative cardiovascular care.
Support & Docs
syngo MBFSiemens Healthineers offers a comprehensive support ecosystem for syngo.via, including dedicated IT Care Plans, professional consulting, education management, and user forums for sharing experiences and accessing educational materials. This structured and multi-faceted approach to support and documentation is more extensive than the standard contact methods provided by Tempus.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | syngo MBF |
|---|---|---|
| Name | Tempus ECG-AF | syngo MBF |
| Company | Tempus AI, Inc. | Siemens Medical Solutions USA, Inc. |
| Description | FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. | FDA-cleared, AI-enhanced software for quantitative myocardial blood flow (MBF) analysis using PET imaging. Integrated within the syngo.via platform, it provides advanced tools for cardiac diagnostics and therapy response assessment. |
| Primary Function | Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months using 12-lead ECG analysis. | Quantitative Myocardial Blood Flow (MBF) and Myocardial Flow Reserve (MFR) calculation using PET imaging. |
| Target Patient Population | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. | Not specified |
| Imaging Modality/Data Type | 12-lead ECG recordings | Dynamic Rubidium-PET and Ammonia-PET images |
| Key Features (selection) | AI-based algorithm for 12-lead ECG analysis; Intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery; Compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems. | Quantitative Myocardial Blood Flow (MBF) and Myocardial Flow Reserve (MFR) calculation; Supports dynamic Rubidium-PET and Ammonia-PET images; Automatic and manual myocardium orientation and segmentation tools; Normals database comparison workflow. |
| CMS Reimbursement | CMS reimbursement available (CPT 0764T and CPT 0765T to APC 5734, Medicare rate of $128.90, effective January 1, 2025). | Contact Vendor for details. |
| Specialties | Cardiology, Geriatrics, Internal Medicine | Cardiology, Nuclear Medicine, Radiology |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and syngo MBF.
Frequently Asked Questions
More Comparisons
More matchups featuring Tempus ECG-AF or syngo MBF
Backers
Who funded each tool's parent company.